SCHEMBL2845680

SCHEMBL2845680

O=C1CC=Cc2ccc3c(c21)Oc1ccccc1O3

nearest known ligand 0.36

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
AHR P35869 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16538009 0.69 MAOA (0.43)
SCHEMBL8791995 0.67 CES1 (0.54)
SCHEMBL3922182 0.66 MAOA (0.43)
SCHEMBL29699894 0.65 NTSR1 (0.33)
SCHEMBL7753388 0.65 MAPT (0.42)
SCHEMBL1399934 0.64 CA12 (0.41) AHR
SCHEMBL29457692 0.64 ALDH1A1 (0.49)
SCHEMBL261907 0.64 CES1 (0.39)
SCHEMBL28346161 0.62
SCHEMBL29385734 0.60 CES1 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10869939-B2 Delivery system in micellar form having modular spectral response based on enzyme-responsive amphiphilic PEG-dendron hybrid polymers RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2020-12-22 US claimed
US-20190162730-A1 METHOD, COMPOSITION AND SENSOR FOR ANALYTE DETECTION SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2019-05-30 US claimed
EP-3469096-A1 METHOD, COMPOSITION AND SENSOR FOR ANALYTE DETECTION Cambridge Display Technology Limited (GB) 2019-04-17 EP claimed
WO-2017216525-A1 METHOD, COMPOSITION AND SENSOR FOR ANALYTE DETECTION CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2017-12-21 WO claimed
US-20170035916-A1 DELIVERY SYSTEM IN MICELLAR FORM HAVING MODULAR SPECTRAL RESPONSE BASED ON ENZYME-RESPONSIVE AMPHIPHILIC PEG-DENDRON HYBRID POLYMERS RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2017-02-09 US claimed
US-9310315-B2 Methods for detecting defects in inorganic-coated polymer surfaces Life Technologies Corporation (US) 2016-04-12 US claimed
CN-103364381-B For detecting the method for the defect in inorganic-coated polymer surfaces LIFE TECHNOLOGIES, INC. (US) 2016-04-06 CN claimed
EP-2554975-A1 Method and substrate for detecting defects in inorganic-coated polymer surfaces Life Technologies Corporation (US) 2013-02-06 EP claimed
US-8304242-B2 Methods for detecting defects in inorganic-coated polymer surfaces Life Technologies Corporation (US) 2012-11-06 US claimed
US-20260048008-A1 ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF OCULAR THERAPEUTIX INC (US) 2026-02-19 US disclosed
EP-4695324-A1 BIO-ORTHOGONAL HYDROGELS FOR SUSTAINED RELEASE DRUG DELIVERY Ocular Therapeutix, Inc. (US) 2026-02-18 EP disclosed
EP-4683964-A2 POLY(ETHYLENE GLYCOL) BASED DENDRIMER-LIKE HYPERBRANCHED MACROMOLECULES, METHODS OF PREPARATION AND USE THEREOF Ocular Therapeutix, Inc. (US) 2026-01-28 EP disclosed
EP-4665307-A1 BIODEGRADABLE MICROPARTICLES FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF Ocular Therapeutix, Inc. (US) 2025-12-24 EP disclosed
EP-4568658-A1 ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF Ocular Therapeutix, Inc. (US) 2025-06-18 EP disclosed
US-20130020507-A1 Methods for Detecting Defects in Inorganic-Coated Polymer Surfaces Life Technologies Corporation (US) 2013-01-24 US disclosed
US-8304242-B2 Methods for detecting defects in inorganic-coated polymer surfaces Life Technologies Corporation (US) 2012-11-06 US disclosed
US-20100291685-A1 METHODS FOR DETECTING DEFECTS IN INORGANIC-COATED POLYMER SURFACES Life Technologies Corporation (US) 2010-11-18 US disclosed
EP-2223087-A2 METHODS FOR DETECTING DEFECTS IN INORGANIC-COATED POLYMER SURFACES Life Technologies Corporation (US) 2010-09-01 EP disclosed
WO-2009079571-A2 METHODS FOR DETECTING DEFECTS IN INORGANIC-COATED POLYMER SURFACES Life Technologies Corporation (US) 2009-06-25 WO disclosed
US-5786219-A POLYMERIC MICROSPHERE DISPLAYING DISTINCT FLUORESCENT RING CONCENTRIC WITH AND WITHIN SAID SPHERE; LABELS, CALIBRATING MICROSCOPES MOLECULAR PROBES, INC. (US) 1998-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048008-A1 ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF KIT, IL33, LY96 AHR 1038/4885
US-20170035916-A1 DELIVERY SYSTEM IN MICELLAR FORM HAVING MODULAR SPECTRAL RESPONSE BASED ON ENZYME-RESPONSIVE AMPHIPHILIC PEG-DENDRON HYBRID POLYMERS JMJD7, HM13, APEH AHR 2362/4885
US-10869939-B2 Delivery system in micellar form having modular spectral response based on enzyme-responsive amphiphilic PEG-dendron hybrid polymers JMJD7, HM13, APEH AHR 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.